Results 231 to 240 of about 78,129 (305)

Exploring the role of granzyme B in subretinal fibrosis of age-related macular degeneration. [PDF]

Front Immunol
Gill K, Yoo HS, Chakravarthy H, Granville DJ, Matsubara JA.   +4 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Potential implications of granzyme B in keloids and hypertrophic scars through extracellular matrix remodeling and latent TGF-β activation. [PDF]

Front Immunol
Aubert A, Goeres J, Liu A, Kao M, Richardson KC, Jung K, Hinz B, Crawford RI, Granville DJ.   +8 more
europepmc   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

Cytolytic too: Granzyme B-expressing human ILC2s mediate tumor rejection. [PDF]

Cell Res
Spits H, Mjösberg J.
europepmc   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, Volume 13, Issue 13, 3 March 2026.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease. [PDF]

J Nucl Med
Heidari P, Haj-Mirzaian A, Prabhu S, Ataeinia B, Esfahani SA, Mahmood U.   +5 more
europepmc   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma. [PDF]

Vet Immunol Immunopathol
Cournoyer A, Amerman H, Assenmacher CA, Durham A, Perry JA, Gedney A, Keuler N, Atherton MJ, Lenz JA.   +8 more
europepmc   +1 more source

Prognostic Impact of Immunoscore in Pathological Stage III Differentiated Gastric Cancer: A Multicenter Cohort Study Including PD‐L1/PD‐L2 Expression Analysis

Annals of Gastroenterological Surgery, Volume 10, Issue 2, Page 431-442, March 2026.
We assessed the prognostic ability of the Immunoscore and PD‐L1 or PD‐L2 expression in pStage III GC patients by immunohistochemistry. The results showed that Immunoscore was an independent prognostic factor in differentiated GC, but not in undifferentiated GC.
Yoshiro Yukawa, Takuro Saito, Yukinori Kurokawa, Yusuke Akamaru, Shinya Kidogami, Hiroshi Imamura, Kazumasa Fujitani, Jin Matsuyama, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Takahiro Matsui, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki   +13 more
wiley   +1 more source